Potential role of miR-9 and miR-223 in recurrent ovarian cancer

Alexandros Laios¹ , Sharon O'Toole¹ , Richard Flavin² , Cara Martin² , Lynne Kelly¹ , Martina Ring² , Stephen P Finn³ , Ciara Barrett² , Massimo Loda³ , Noreen Gleeson¹ , Tom D'Arcy¹ , Eamonn McGuinness¹ , Orla Sheils² , Brian Sheppard¹ and John O' Leary²

¹Department of Obstetrics and Gynaecology, Trinity College Dublin, Trinity Centre for Health Sciences, St. James's Hospital, Dublin 8, Ireland

²Department of Histopathology, Trinity College Dublin, Trinity Centre for Health Sciences, St James's Hospital, Dublin 8, Ireland

³The Dana Faber Cancer Institute, Harvard Medical School, Boston, MA, USA

author email corresponding author email

Molecular Cancer 2008, 7:35doi:10.1186/1476-4598-7-35


Published:	28 April 2008

Additional files

Additional file 1:

miRNA genes differentially expressed between recurrent and primary serous papillary ovarian adenocarcinomas in the training cohort with their numerical fold changes ranging from 2 to 11. Common miRNA genes highlighted in red have been identified as differentially expressed in diverse cancers. This signifies that specific miRNAs are involved in common molecular pathways. miRNAs highlighted in green were the top dysregulated in recurrent vs primary serous papillary adenocarcinomas in the training cohort.

Format: XLS Size: 16KB Download file

This file can be viewed with: Microsoft Excel Viewer